Skip to main content
Fig. 6 | BMC Cancer

Fig. 6

From: A type I combi-targeting approach for the design of molecules with enhanced potency against BRCA1/2 mutant- and O6-methylguanine-DNA methyltransferase (mgmt)- expressing tumour cells

Fig. 6

Anomalously strong DNA damaging potential of EG22 after a 2 h drug treatment as compared with temozolomide (TMZ) and ANI + TMZ in the Chinese lung cancer cell lines VC8 and V79. The cells were exposed to the drugs (EG22, TMZ, ANI and ANI + TMZ) for 2 h, and subsequently harvested with trypsin EDTA, centrifuged and resuspended twice in PBS. Comet assay was performed as per Materials and Methods. Comets were visualized at 400X magnification and DNA damage measured as tail moments using Comet Assay IV software

Back to article page